Inclusion Criteria:

- Male or female subjects, ages 18 years and older who have received a primary liver
transplant from a deceased donor for ESLD.

- Women of child-bearing potential must have a negative serum pregnancy test at the
time of screening and agree to use a medically acceptable method of contraception
throughout the study and for 3 months following discontinuation of study treatment.

Exclusion Criteria:

- Recipients of multi-organ transplants.

- Recipients with positive crossmatch with their donor (current or previously).

- Subjects with a screening white blood cell count ≤ 2,000 mm3 or ANC ≤ 1000, platelet
count ≤ 100,000 mm3.

- Recipients with a hematocrit < 32.

- History of malignancy within 5 years of enrollment (except for adequately treated
basal cell or squamous cell carcinoma of the skin).

- Subjects who are positive for hepatitis C, hepatitis B surface antigen, or HIV.

- Subjects with previous intolerance to full dose MPA agent.

- Subjects with a history of acute rejection within 6 months prior to study enrollment.

- Subjects who have had chronic ductopenic rejection.

- Subjects who had rejection in the first-year post-transplant and are less than 3
years post-transplant.

- Subjects who had rejection requiring treatment with thymoglobulin or OKT3 at anytime
post-transplant.

- Original cause of ESLD related to autoimmune diseases such as autoimmune hepatitis,
primary biliary cirrhosis, and primary sclerosing cholangitis.

- Subjects who have received an investigational drug within 4 weeks of study entry.

- Subjects with a history of a psychological illness or condition such as to interfere
with the subject's ability to understand the requirements of the study.

- Female subjects who are pregnant or nursing or females who are unwilling to use
contraception during the study.

- Subjects who are currently receiving any therapy for immunosuppression other than a
MPA agent and tacrolimus.

- Subjects with a history of hepatocellular carcinoma (T2 >).

- Subjects with severe coexisting disease or presenting with any unstable medical
condition which could affect study objectives.

- Subjects who have a known hypersensitivity to tacrolimus or mycophenolate